Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).

about

Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.

P2860

Q38813392-A248CC57-21AD-4B23-9E70-EFA4B0CC8FCF

P2860

Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).

Item

http://www.wikidata.org/entity/Q41002762

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Highly effective reduced toxic ...... osteogenic sarcoma (SCOS 89).

@en

type

Item

label

Highly effective reduced toxic ...... osteogenic sarcoma (SCOS 89).

@en

prefLabel

Highly effective reduced toxic ...... osteogenic sarcoma (SCOS 89).

@en

P1476

Highly effective reduced toxic ...... b osteogenic sarcoma (SCOS 89)

@en

P2093

Helen Toledano

http://www.w3.org/2001/XMLSchema#string

Isaac Yaniv

http://www.w3.org/2001/XMLSchema#string

Josephine Issakov

http://www.w3.org/2001/XMLSchema#string

Shifra Ash

http://www.w3.org/2001/XMLSchema#string

Vered Shkalim-Zemer

http://www.w3.org/2001/XMLSchema#string

Yehuda Kollender

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-response effect of adjuvant chemotherapy in breast cancer

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study

A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.

Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.

P2888

s00280-015-2865-x

P304

909-916

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-015-2865-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ian J Cohen

P577

2015-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043930199

http://www.w3.org/2001/XMLSchema#string

P698

26365289

http://www.w3.org/2001/XMLSchema#string

Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).

about

P2860

P2860

Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698